Arcturus Therapeutics Holdings Stock Earnings Reports

Arcturus reported progress across its rare disease mRNA pipeline in Q1 2026. Key clinical updates: enrollment has begun in a 12-week open-label Phase II study of inhaled mRNA candidate ARCT-032 for Class I cystic fibrosis (CF); the study is already dosing beyond one month and will capture FEV1, lung clearance index (LCI), HRCT and quality-of-life measures to assess safety, tolerability and early efficacy. For the liver program ARCT-810 (OTC deficiency), the company had Type C discussions with the FDA and received clear regulatory direction toward a pediatric pivotal path; additional exploratory data are being collected and an end-of-Phase II meeting is planned for H2 2026. Commercial partner Meiji is manufacturing the self-amplifying mRNA COVID vaccine KOSTAIVE for Japan, with commercial guidance coming from Meiji. Leadership was strengthened with Dennis Mulroy (CFO) and Dr. Alan Cohen (CMO) joining. Financially, cash, cash equivalents and restricted cash were $213.4M as of March 31, 2026 (down from $232.8M at year-end), revenue declined year-over-year due to refocusing away from certain collaborations, and R&D and G&A expenses decreased; management states the cash runway extends beyond Q2 2028 to support near-term milestones. Management highlighted technological differentiators (unique LUNAR inhaled particle chemistry and proprietary mRNA purification) as reasons for observed tolerability and for differentiating Arcturus from other inhaled mRNA efforts.